Investing in BranchLab: AI-Native Solutions for Healthcare Marketers
Powering a new era of privacy-first, outcome-driven advertising.
The U.S. healthcare digital audience market, despite being fueled by tens of billions in pharmaceutical marketing spend, remains defined by three structural challenges. First, it is anchored to commoditized datasets, with most incumbents licensing the same claims assets and producing largely indistinguishable outputs. Second, deterministic segments face increasing dilution under privacy rules, capping precision and efficiency. Third, vendors tend to adjust only after regulations change, leaving clients exposed to ongoing legal and compliance risk.
Against this backdrop, the next winners will be those that combine unassailable compliance, giving clients confidence that budgets are protected from regulatory volatility, with differentiated data access that unlocks net-new, high-quality audiences beyond the industry-wide overlap.
BranchLab has emerged as the clear challenger built to solve for both. Its AI-native Pathwai™ platform allows brands, agencies, and media partners to transform their own non-health data into outcome-based audiences optimized for real-world metrics such as prescriptions, diagnoses, and visits. This converts previously untapped datasets into strategic assets, delivering precision at scale while operating within a compliance-by-design framework.
The result is a fundamentally different model for healthcare marketing. Where incumbents treat privacy as a constraint, BranchLab has embedded it as the foundation of its architecture. Everyday non-health attributes become predictive indicators of health outcomes, enabling engagement that is both earlier and more relevant. This isn’t just about improving access to drugs and therapies—it’s about meeting patients earlier in their care journey, when interventions can make the greatest difference.
For brands/enterprises, this means stronger reach and efficiency. For publishers and CRM holders, it unlocks the ability to generate proprietary health audiences, expanding the overall supply of addressable segments. This dual value proposition of demand-side precision and supply-side democratization positions BranchLab not merely as another audience vendor but as the substrate for a more decentralized, privacy-forward ecosystem.
In a market undergoing structural change, BranchLab is uniquely equipped to capture budget reallocations away from legacy models and toward platforms that combine compliance, scale, and predictive accuracy.
We are excited to partner with Josh, Michael, and Dan, who together bring over four decades of experience building and scaling data-driven technology platforms. Josh co-founded AdTheorent and led it through IPO, pioneering outcome-based predictive modeling at scale, while Michael and Dan bring executive leadership from Amazon Prime Video, VideoAmp, and other leading companies at the intersection of media, data, and technology.
Every month we write a piece encompassing themes within our whole-person health investment thesis. If you would like to receive it directly in your inbox, subscribe now.